Tag Archives: GLP-1 therapies

What happens when breakthrough treatments only reach the few who can afford or access them? That’s the growing dilemma in diabetes care. As GLP‑1 medications, digital tools, and AI reshape how we treat this chronic disease, the risk is clear: innovation could deepen inequality if we don’t act intentionally. Equity …

What happens when a guideline finally reflects the complex realities of patient care? The ADA’s 2026 CKM standards aim to do just that—merging heart, kidney, and metabolic health into one actionable framework. But translating those recommendations into daily clinical decision-making isn’t always straightforward. This article walks through real-world composite cases …

What happens when medications become easier to take—but harder to track? Oral and monthly GLP‑1 therapies promise fewer injections and less hassle, yet they may also create blind spots in patient care. As these long‑acting options reshape diabetes treatment, they’re also changing how clinicians must think about follow‑up, side effect …

In recent years, GLP‑1-based treatments for obesity have evolved from being primarily a diabetes-focused strategy to becoming a powerful tool for managing weight and reducing cardiometabolic risk—especially in individuals without type 2 diabetes. This growing trend is shifting how clinicians identify and manage obesity, moving beyond A1C levels to a …